What Is LDH (Lactate Dehydrogenase)? Normal vs Optimal Range Explained

LDH exists in virtually every tissue in the body—heart, liver, kidneys, skeletal muscle, red blood cells, brain, and lungs all contain high concentrations of this enzyme. When cells in any of these tissues are damaged, LDH leaks into the bloodstream and levels rise. The CTD maps over 1,400 compound interactions affecting LDH expression, reflecting the enzyme's ubiquity across metabolic pathways. Lab reference ranges extending to 280 U/L include values where mild ongoing tissue damage may already be present. LDH between 240 and 280 U/L in someone without acute illness or recent intense exercise warrants investigation for subclinical hemolysis, occult liver injury, or early lymphoproliferative disease. The optimal range of 140–240 U/L reflects baseline cellular turnover without pathological tissue destruction. Persistently elevated LDH between 240 and 280 U/L across multiple blood draws—after ruling out exercise, hemolyzed samples, and medication effects—should prompt systematic investigation with organ-specific companion markers to identify the tissue source before damage progresses.

The clinical power of LDH lies not in its specificity but in its sensitivity as a general alarm. PubMed indexes over 120,000 publications referencing LDH, with clinical analyses using it as a prognostic marker in lymphoma (where LDH level at diagnosis predicts survival), pulmonary embolism (where elevated LDH with normal troponin helps differentiate PE from myocardial infarction), melanoma staging, hemolytic anemia monitoring, and sepsis severity assessment. LDH isoenzyme fractionation can narrow the source—LDH-1 and LDH-2 predominate in heart and red blood cells, LDH-3 in lung and platelets, LDH-4 and LDH-5 in liver and skeletal muscle. However, total LDH combined with organ-specific markers (ALT for liver, troponin for heart, haptoglobin for hemolysis) is more practical and widely used than isoenzyme testing. In oncology, LDH carries particular prognostic weight: the International Prognostic Index for aggressive lymphoma incorporates LDH as one of five factors predicting overall survival, and melanoma staging systems use LDH elevation to identify Stage IV disease with the worst prognosis.

Several common situations produce LDH elevation without pathological tissue destruction. FAERS data document LDH changes across over 100 medication entries. Intense exercise releases LDH from muscle cells—marathon runners commonly show LDH two to three times the upper limit for 24 to 48 hours after a race. Hemolysis during blood draw from a traumatic venipuncture or prolonged tourniquet can falsely elevate LDH by releasing enzyme from ruptured red blood cells in the sample rather than in the patient. Medications including methotrexate, certain chemotherapy agents, and antiretrovirals can directly cause LDH elevation through hepatotoxicity or myotoxicity. Trending LDH over time provides more clinical value than any single measurement—a rising LDH in a cancer patient suggests disease progression, while a falling LDH during treatment suggests response. In critically ill patients, serial LDH tracking provides a real-time window into the trajectory of multi-organ injury—a steadily declining LDH reassures clinicians that tissue damage is resolving, while a secondary rise after initial improvement may signal a new complication requiring immediate investigation.